ANAVEX
Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. The Anavex portfolio comprises novel, wholly owned sigma receptor agonists and antagonists. The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose (SAD) clinical trial. The company has also started scale-up manufacturing for ANAVEX 1-41, its second lead compound, targeting depression and AD. With sufficient quantities of ANAVEX 1-41 in hand, the company will be in a position to advance the program and begin preclinical studies on large animals in the near term.
ANAVEX
Industry:
Biopharma Biotechnology Health Care Manufacturing Therapeutics
Founded:
2006-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.anavex.com
Total Employee:
1+
Status:
Active
Contact:
14164890092
Email Addresses:
[email protected]
Total Funding:
62.6 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Domain Not Resolving Sitelinks Search Box GStatic Google Static Content COVID-19 Sectigo SSL
Similar Organizations
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Anavex
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-06 | Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer |
Official Site Inspections
http://www.anavex.com Semrush global rank: 1.81 M Semrush visits lastest month: 12.54 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Anavex"
About Us | Anavex Life Sciences
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a person-focused, biopharmaceutical company dedicated to therapeutic discovery and development of targeted CNS treatments. Our Values. …See details»
Anavex - Crunchbase Company Profile & Funding
Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery …See details»
Corporate Governance - Anavex Life Sciences
Corporate governance documents available for download and review.See details»
Anavex Life Sciences - LinkedIn
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and ...See details»
Anavex Lf SC (AVXL-Q) Profile - The Globe and Mail
Jul 24, 2011 See the company profile for Anavex Lf SC (AVXL-Q) including business summary, industry/sector information, business summary, corporate governance, key executives.See details»
Anavex Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of …See details»
Anavex Life Sciences Announces Acceptance of Peer ... - Morningstar
4 days ago NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company …See details»
Anavex Life Sciences Announces Submission of …
3 days ago First marketing authorization submission for blarcamesine. There are an estimated 7 million people in Europe with Alzheimer’s disease, a number expected to double by 2030, according to the European Brain Council. [2] The …See details»
Anavex - Funding, Financials, Valuation & Investors - Crunchbase
Anavex is a biopharmaceutical company developing drugs for the treatment of cancer and neurological diseases. Search Crunchbase. Start Free Trial . Chrome Extension. ... How much …See details»
Anavex Life Sciences Announces Submission of Blarcamesine MAA …
3 days ago ANAVEX ® 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS …See details»
Anavex Life Sciences Announces Acceptance of Peer-Reviewed …
4 days ago NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company …See details»
Anavex Life Sciences Announces Acceptance of Peer-Reviewed
4 days ago Anavex's lead drug candidate, ANAVEX ® 2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof …See details»
Investors - Anavex Life Sciences
Anavex Life Sciences Corp. cannot be sure when or if it will be permitted by regulatory agencies to undertake clinical trials or to commence any particular phase of any clinical trials. Because …See details»
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in …
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing …See details»
Anavex Life Sciences Corp. (AVXL) - Yahoo Finance
Find the latest Anavex Life Sciences Corp. (AVXL) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Anavex Life Sciences Announces Submission of Blarcamesine
3 days ago Anavex's lead drug candidate, ANAVEX ® 2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof …See details»
Anavex Life Sciences (AVXL) Earnings Date and Reports 2024
2 days ago Anavex Life Sciences (NASDAQ:AVXL) has a recorded net income of -$47.51 million. AVXL has generated -$0.50 earnings per share over the last four quarters. What is …See details»
Anavex Life Sciences Announces Expansion of Leadership Team
May 22, 2024 Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof …See details»
Anavex Life Sciences Announces Acceptance of Peer-Reviewed …
4 days ago For Further Information: Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: [email protected]. Investors: Andrew J. BarwickiSee details»
Anavex Life Sciences Announces Acceptance of Peer-Reviewed …
4 days ago Anavex today announced the acceptance of a peer-reviewed manuscript titled, “Blarcamesine for the treatment of Early Alzheimer’s Disease: Results from the ANAVEX2-73 …See details»